Thrombocytosis in EPO-Treated Dialysis Patients May Be Mediated by EPO Rather Than Iron Deficiency Nosratola D. Vaziri, MD American Journal of Kidney Diseases Volume 53, Issue 5, Pages 733-736 (May 2009) DOI: 10.1053/j.ajkd.2008.12.030 Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions
Figure 1 Effects of high doses of erythropoietin on platelet production, platelet activity, and potential risks of thromboembolism and cardiovascular disease. Abbreviations: [Ca2+]i, intracellular ionized calcium concentration; vWF, von Willebrand factor. American Journal of Kidney Diseases 2009 53, 733-736DOI: (10.1053/j.ajkd.2008.12.030) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions